Time-dependent Changes of Oxime K027 Concentrations in Different Parts of Rat Central Nervous System

Overview

Journal Neurotox Res

Publisher Springer

Specialty Neurology

Date 2012 May 16

PMID 22585538

Citations 7

Authors

Jana Zdarova Karasova

Filip Zemek

Kamil Musilek

Kamil Kuca

Affiliations

Soon will be listed here.

Abstract

The blood-brain barrier plays a vital role in the protection of the central nervous system. It is composed of endothelial cells with tight-junctions to limit the penetration of many endogenous and exogenous compounds, particularly hydrophilic xenobiotics. Nerve agents and pesticides are groups of compounds with high penetration potential into the central nervous system. However, oxime type antidotes are known to penetrate blood-brain barrier only in low concentration. The aim of presented study is to describe the pharmacokinetic profile of oxime K027 a novel antidote candidate. The main focus is on penetration of tested substance into the selected brain regions following time-dependent manner. The maximum concentration of the oxime K027 was attaining 15 and 30 min after i.m. application in plasma and brain tissue, respectively. The perfused brain tissue concentration was relatively high (10(-7) M order of magnitude) and depending on the brain region it was constant 15-60 min after application. The highest concentration was found in the frontal cortex 15 min after application while the lowest measured concentration was determined in the basal ganglia. This study showed that oxime K027 is able to achieve high concentration level in perfused brain tissue relatively quickly, but also demonstrated rapid clearance from the central nervous system. These results are probably due to low overall uptake of oxime K027 into the brain.

Citing Articles

Brominated oxime nucleophiles are efficiently reactivating cholinesterases inhibited by nerve agents.

Prchalova E, Andrys R, Pejchal J, Kohoutova Z, Knittelova K, Hofmanova T Arch Toxicol. 2024; 98(9):2937-2952.

PMID: 38789714 DOI: 10.1007/s00204-024-03791-6.

Recent developments on oximes to improve the blood brain barrier penetration for the treatment of organophosphorus poisoning: a review.

Norrrahim M, Razak M, Ahmad Shah N, Kasim H, Wan Yusoff W, Halim N RSC Adv. 2022; 10(8):4465-4489.

PMID: 35495228 PMC: 9049292. DOI: 10.1039/c9ra08599h.

Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats.

Zdarova Karasova J, Hrabinova M, Krejciova M, Jun D, Kuca K Iran J Pharm Res. 2021; 19(3):95-102.

PMID: 33680013 PMC: 7758017. DOI: 10.22037/ijpr.2019.1100723.

Development of versatile and potent monoquaternary reactivators of acetylcholinesterase.

Gorecki L, Hepnarova V, Zdarova Karasova J, Hrabinova M, Courageux C, Dias J Arch Toxicol. 2021; 95(3):985-1001.

PMID: 33517499 DOI: 10.1007/s00204-021-02981-w.

Interaction of Cucurbit[7]uril with Oxime K027, Atropine, and Paraoxon: Risky or Advantageous Delivery System?.

Zdarova Karasova J, Mzik M, Kucera T, Vecera Z, Kassa J, Sestak V Int J Mol Sci. 2020; 21(21).

PMID: 33114215 PMC: 7672622. DOI: 10.3390/ijms21217883.

References

Kassa J, Kuca K, Karasova J, Musilek K . The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun. Mini Rev Med Chem. 2008; 8(11):1134-43. DOI: 10.2174/138955708785909871. View

Garcia G, Campbell A, Olson J, Moorad-Doctor D, Morthole V . Novel oximes as blood-brain barrier penetrating cholinesterase reactivators. Chem Biol Interact. 2010; 187(1-3):199-206. DOI: 10.1016/j.cbi.2010.02.033. View

Zdarova Karasova J, Chladek J, Hroch M, Josef F, Hnidkova D, Kuca K . Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma. J Appl Toxicol. 2011; 33(1):18-23. DOI: 10.1002/jat.1699. View

Petroianu G, Hasan M, Nurulain S, Nagelkerke N, Kassa J, Kuca K . New K-Oximes (K-27 and K-48) in Comparison with Obidoxime (LuH-6), HI-6, Trimedoxime (TMB-4), and Pralidoxime (2-PAM): Survival in Rats Exposed IP to the Organophosphate Paraoxon. Toxicol Mech Methods. 2009; 17(7):401-8. DOI: 10.1080/15376510601131362. View

Bajgar J, Fusek J, Kassa J, Jun D, Kuca K, Hajek P . An attempt to assess functionally minimal acetylcholinesterase activity necessary for survival of rats intoxicated with nerve agents. Chem Biol Interact. 2008; 175(1-3):281-5. DOI: 10.1016/j.cbi.2008.05.015. View

Lorke D, Kalasz H, Petroianu G, Tekes K . Entry of oximes into the brain: a review. Curr Med Chem. 2008; 15(8):743-53. DOI: 10.2174/092986708783955563. View

Pohanka M, Novotny L, Misik J, Kuca K, Zdarova-Karasova J, Hrabinova M . Evaluation of cholinesterase activities during in vivo intoxication using an electrochemical sensor strip - correlation with intoxication symptoms. Sensors (Basel). 2012; 9(5):3627-34. PMC: 3297120. DOI: 10.3390/s90503627. View

Feng M . Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab. 2002; 3(6):647-57. DOI: 10.2174/1389200023337063. View

Bajgar J, Zdarova Karasova J, Kassa J, Cabal J, Fusek J, Blaha V . Tabun-inhibited rat tissue and blood cholinesterases and their reactivation with the combination of trimedoxime and HI-6 in vivo. Chem Biol Interact. 2010; 187(1-3):287-90. DOI: 10.1016/j.cbi.2010.02.009. View

10.

Terasaki , Hosoya . The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev. 2000; 36(2-3):195-209. DOI: 10.1016/s0169-409x(98)00088-x. View

11.

Amourette C, Lamproglou I, Barbier L, Fauquette W, Zoppe A, Viret R . Gulf War illness: Effects of repeated stress and pyridostigmine treatment on blood-brain barrier permeability and cholinesterase activity in rat brain. Behav Brain Res. 2009; 203(2):207-14. DOI: 10.1016/j.bbr.2009.05.002. View

12.

Kuca K, Bielavsky J, Cabal J, Kassa J . Synthesis of a new reactivator of tabun-inhibited acetylcholinesterase. Bioorg Med Chem Lett. 2003; 13(20):3545-7. DOI: 10.1016/s0960-894x(03)00751-0. View

13.

Petroianu G, Lorke D, Hasan M, Adem A, Sheen R, Nurulain S . Paraoxon has only a minimal effect on pralidoxime brain concentration in rats. J Appl Toxicol. 2007; 27(4):350-7. DOI: 10.1002/jat.1213. View

14.

Voicu V, Sora I, Sarbu C, David V, Medvedovici A . Hydrophobicity/hydrophilicity descriptors obtained from extrapolated chromatographic retention data as modeling tools for biological distribution: application to some oxime-type acetylcholinesterase reactivators. J Pharm Biomed Anal. 2010; 52(4):508-16. DOI: 10.1016/j.jpba.2010.02.004. View

15.

Sakurada K, Matsubara K, Shimizu K, Shiono H, Seto Y, Tsuge K . Pralidoxime iodide (2-pAM) penetrates across the blood-brain barrier. Neurochem Res. 2003; 28(9):1401-7. DOI: 10.1023/a:1024960819430. View

16.

Pardridge W . Brain drug development and brain drug targeting. Pharm Res. 2007; 24(9):1729-32. DOI: 10.1007/s11095-007-9387-0. View

17.

Kassa J, Zdarova Karasova J, Caisberger F, Musilek K, Kuca K, Jung Y . A comparison of reactivating and therapeutic efficacy of the oxime K203 and its fluorinated analog (KR-22836) with currently available oximes (obidoxime, trimedoxime, HI-6) against tabun in rats and mice. J Enzyme Inhib Med Chem. 2010; 25(4):480-4. DOI: 10.3109/14756360903257918. View

18.

Kuca K, Musilek K, Jun D, Pohanka M, Ghosh K, Hrabinova M . Oxime K027: novel low-toxic candidate for the universal reactivator of nerve agent- and pesticide-inhibited acetylcholinesterase. J Enzyme Inhib Med Chem. 2010; 25(4):509-12. DOI: 10.3109/14756360903357569. View

19.

Loscher W, Potschka H . Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005; 76(1):22-76. DOI: 10.1016/j.pneurobio.2005.04.006. View

20.

Ueno M, Nakagawa T, Wu B, Onodera M, Huang C, Kusaka T . Transporters in the brain endothelial barrier. Curr Med Chem. 2010; 17(12):1125-38. DOI: 10.2174/092986710790827816. View